CN116637158A - Anti-influenza virus traditional Chinese medicine composition and preparation method thereof - Google Patents
Anti-influenza virus traditional Chinese medicine composition and preparation method thereof Download PDFInfo
- Publication number
- CN116637158A CN116637158A CN202310648820.0A CN202310648820A CN116637158A CN 116637158 A CN116637158 A CN 116637158A CN 202310648820 A CN202310648820 A CN 202310648820A CN 116637158 A CN116637158 A CN 116637158A
- Authority
- CN
- China
- Prior art keywords
- parts
- sang
- influenza virus
- fang
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 241000700605 Viruses Species 0.000 title claims description 50
- 206010022000 influenza Diseases 0.000 title claims description 46
- 238000002360 preparation method Methods 0.000 title claims description 11
- 241000334154 Isatis tinctoria Species 0.000 claims abstract description 17
- 240000000249 Morus alba Species 0.000 claims abstract description 17
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 17
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 17
- 239000010440 gypsum Substances 0.000 claims abstract description 17
- 235000014676 Phragmites communis Nutrition 0.000 claims abstract description 16
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 15
- 244000018633 Prunus armeniaca Species 0.000 claims abstract description 15
- 235000009827 Prunus armeniaca Nutrition 0.000 claims abstract description 15
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 14
- 244000281702 Dioscorea villosa Species 0.000 claims abstract 4
- 241000050051 Chelone glabra Species 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 229940079593 drug Drugs 0.000 claims description 30
- 238000001914 filtration Methods 0.000 claims description 12
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 11
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 10
- 235000011477 liquorice Nutrition 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000007865 diluting Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 241000628997 Flos Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 89
- 210000004072 lung Anatomy 0.000 abstract description 64
- 241000712461 unidentified influenza virus Species 0.000 abstract description 54
- 230000000694 effects Effects 0.000 abstract description 50
- 210000003837 chick embryo Anatomy 0.000 abstract description 48
- 208000024891 symptom Diseases 0.000 abstract description 37
- 238000011282 treatment Methods 0.000 abstract description 33
- 238000002474 experimental method Methods 0.000 abstract description 23
- 230000035931 haemagglutination Effects 0.000 abstract description 15
- 208000011580 syndromic disease Diseases 0.000 abstract description 14
- 230000008901 benefit Effects 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000007119 pathological manifestation Effects 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 3
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 62
- 229960003752 oseltamivir Drugs 0.000 description 41
- 210000001519 tissue Anatomy 0.000 description 23
- 230000037396 body weight Effects 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 19
- 230000007170 pathology Effects 0.000 description 17
- 241000287828 Gallus gallus Species 0.000 description 15
- 235000013330 chicken meat Nutrition 0.000 description 15
- 240000005717 Dioscorea alata Species 0.000 description 13
- 206010037660 Pyrexia Diseases 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 230000029058 respiratory gaseous exchange Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000001161 mammalian embryo Anatomy 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 208000027744 congestion Diseases 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 238000000465 moulding Methods 0.000 description 9
- 241000207929 Scutellaria Species 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 230000008595 infiltration Effects 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 231100000636 lethal dose Toxicity 0.000 description 8
- 230000006996 mental state Effects 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 208000010201 Exanthema Diseases 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000036528 appetite Effects 0.000 description 6
- 235000019789 appetite Nutrition 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000005884 exanthem Diseases 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 206010037844 rash Diseases 0.000 description 6
- 230000011514 reflex Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000013872 defecation Effects 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 210000002741 palatine tonsil Anatomy 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000003278 egg shell Anatomy 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 239000007923 nasal drop Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010069767 H1N1 influenza Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 240000004534 Scutellaria baicalensis Species 0.000 description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000021760 high fever Diseases 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000036244 malformation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000004879 pulmonary tissue Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 201000010740 swine influenza Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000009701 Embryo Loss Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000282339 Mustela Species 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 210000001643 allantois Anatomy 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 230000005727 virus proliferation Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000131458 Elsholtzia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 235000013717 Houttuynia Nutrition 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- 241001071917 Lithospermum Species 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 235000003893 Prunus dulcis var amara Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000951473 Schizonepeta Species 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000017804 lesions in lung Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108010025496 mucin receptor Proteins 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
- A61K36/855—Clerodendrum, e.g. glorybower
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for resisting influenza virus, which is characterized in that: the proportion of each component is as follows: 15 parts of dyers woad leaf, 9 parts of mulberry leaf, 12 parts of reed rhizome, 9 parts of baical skullcap root, 30 parts of gypsum, 6 parts of chrysanthemum, 6 parts of bitter apricot seed, 9 parts of Ningpo Yam rhizome and 4 parts of liquoric root. The Qing Sang Fang disclosed by the invention has the effects of clearing heat and detoxicating, relieving exterior syndrome and ventilating the lung, and has the effects of strengthening body resistance (improving immunity). The qing Sang Fang provided by the invention not only has a better curative effect in clinic, but also takes up a great advantage in price, and obtains higher acceptance of parents of children patients. According to the invention, the influence of the green Sang Fang on the hemagglutination titer of the influenza virus in the chick embryo and the treatment effect of infected mice are researched by two experimental examples, so that a theoretical basis is provided for resisting the influenza virus in the traditional Chinese medicine; experiments show that the green Sang Fang has an inhibiting effect on the hemagglutination titer of the influenza virus, can improve the symptoms, the weight, the lung index, the pathological manifestations and the scores of mice, and proves the reliability of the formula.
Description
Technical Field
The invention belongs to the technical field of anti-influenza traditional Chinese medicines, and in particular relates to an anti-influenza traditional Chinese medicine composition and a preparation method thereof.
Background
Influenza (influenza for short) is a respiratory disease caused by influenza virus. Symptoms such as hyperpyrexia, muscular soreness, weakness and the like are main clinical manifestations, and some children may have atypical gastrointestinal symptoms such as vomiting, diarrhea and the like.
The traditional Chinese medicine corresponding to influenza is named as "time-consuming cold", exogenous pestilence toxin epidemic pathogenic factors and deficiency of vital qi are two main causes of disease, the disease location is usually in lung defensive qi, but spleen and stomach are easily involved, the heart is invading by serious people, and the total pathogenesis is epidemic toxin exogenous pathogenic factors and attack lung defensive qi.
Oseltamivir is the western medicine with the best treatment and prevention effects in clinic at present, and is suitable for influenza A (A) and influenza B (B). However, it is required to take the medicine within 48 hours of symptoms of infection to obtain the best curative effect; from 2008, reports of drug resistance of oseltamivir are gradually increased, and the highest drug resistance rate of some countries can reach 67.3%.
The children influenza virus pneumonia still has higher fatality rate. The traditional Chinese medicine has unique advantages in preventing and treating infectious diseases such as influenza and the like, and accumulates rich theoretical and clinical experience for thousands of years.
In recent years, the research of traditional Chinese medicine becomes a popular direction for resisting influenza virus, and more clinical experience reports are provided, and the invention patent is also published. However, there are still certain limitations in the published anti-influenza patents, including: the traditional Chinese medicine has the advantages of multiple medicine tastes, heavy bitter taste and poor compliance of children; the influenza syndrome type applicable to the medicine is not obvious: some drugs still contain components of the bib , affect safety, etc. For example, "a traditional Chinese medicine mixture for treating viral influenza and a preparation method thereof," application number (201410223497.3): 60 parts of gypsum, 150 parts of cordate houttuynia, 150 parts of platycodon grandiflorum, 60 parts of bitter apricot seed, 120 parts of chrysanthemum, 150 parts of mulberry leaf, 60 parts of schizonepeta, 90 parts of peppermint, 150 parts of reed rhizome, 150 parts of weeping forsythia, 90 parts of perilla leaf, 120 parts of rhizoma anemarrhenae, 150 parts of honeysuckle, 90 parts of baical skullcap root, 120 parts of elsholtzia, 150 parts of kudzuvine root, 90 parts of liuyisan, 150 parts of dyers woad leaf, 120 parts of lithospermum, 150 parts of isatis root and 60 parts of liquorice, wherein 22 types (including six yisan) of the total weight of the traditional Chinese medicine composition are obtained, and only clinical case statistics data are lacked; meanwhile, children are not mainly used as treatment objects.
Through animal experiments, the anti-influenza curative effect of the traditional Chinese medicine can be better verified, related action mechanisms are discussed, and more reliable support is provided for clinical popularization and use.
The domestic influenza is summarized and summarized into 7 types of syndromes by combining with the latest diagnosis and treatment scheme and expert consensus guidance of the country, and the corresponding treatment methods, ancient prescription and provenance and symptoms are shown in table 1.
The green Sang Fang of the invention is added and subtracted on the basis of Maxingshi Gantn Tang Mulberry leaf-chrysanthemum drink according to clinical experience. Is mainly suitable for wind-heat invading exterior syndrome, and the syndrome: high fever, slight aversion to cold, debilitation, pharyngalgia, headache, body pain, conjunctival congestion, cough and asthma and the like, and has good effects.
Disclosure of Invention
Aiming at the technical problems, the invention provides an anti-influenza virus traditional Chinese medicine composition and a preparation method thereof. Influenza is usually caused by epidemic toxin invading the body and struggling with the healthy qi and pathogenic factors, which causes fever, weakness, headache and body pain, etc., and toxic heat is paced in the throat to cause reddish swelling and pain. The lung is prone to feel exogenous pathogenic factors and has weakened dispersing function, and the descending and incorporating forces are not good enough, so that the lung qi is reversed and the cough and asthma are caused. Therefore, qing Sang Fang takes clearing heat and detoxicating, relieving exterior syndrome and ventilating lung as a treatment method, and has the effects of strengthening body resistance (improving immunity), and is suitable for wind-heat invading exterior syndrome caused by influenza virus infection. The green Sang Fang of the invention has the characteristics of few medicinal herbs, bitter Xin Weidan, easy taking by children, good clinical antipyretic and cough relieving effects and the like. Experimental example researches show that the green Sang Fang has antipyretic effect on experimental rats, influence on the hemagglutination titer of influenza viruses in chick embryos and treatment effect on infected mice, and provides theoretical basis for anti-influenza viruses of traditional Chinese medicines; experiments show that the green Sang Fang has an inhibiting effect on the hemagglutination titer of influenza viruses, and can improve the symptoms, the weight, the lung index, the pathological manifestations and the scores of mice, thereby proving the reliability of the influenza virus resistance of the formula. The infant who is clinically determined to be diagnosed with influenza virus infection has good treatment effect by using the green Sang Fang.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
a Chinese medicinal composition for resisting influenza virus comprises folium Isatidis, folium Mori, rhizoma Phragmitis, scutellariae radix, gypsum Fibrosum, flos Chrysanthemi, semen Armeniacae amarum, ningpo Yam rhizome and Glycyrrhrizae radix.
Preferably, the proportions of the components are: 15 parts of dyers woad leaf, 9 parts of mulberry leaf, 12 parts of reed rhizome, 9 parts of baical skullcap root, 30 parts of gypsum, 6 parts of chrysanthemum, 6 parts of bitter apricot seed, 9 parts of Ningpo Yam rhizome and 4 parts of liquoric root.
A preparation method of an anti-influenza virus traditional Chinese medicine composition comprises the following steps:
step 1: decocting 3 agents, namely 300g of gypsum with 300ml of pure water with strong fire for 15-30min;
step 2: 150 parts of dyers woad leaf, 90 parts of mulberry leaf, 120 parts of reed rhizome, 90 parts of baical skullcap root, 60 parts of chrysanthemum, 60 parts of bitter apricot seed, 90 parts of Ningpo Yam rhizome and 40 parts of liquorice are added into the medicine in the step 1, and 1500ml of pure water is added for soaking for 1 hour;
step 3: heating and decocting all the medicines in the step 2 with slow fire to 300mL, filtering the decoction with 4 layers of sterile gauze, collecting the filtered decoction, adding 1500mL of pure water into the residual filter residue, heating and decocting with slow fire to 300mL again, repeating the filtering and decocting operation for 5 times, finally combining the 5 times of filtrates, and concentrating the medicines to 6g/mL;
step 4: sterilizing the medicine prepared in the step 3 at high temperature and high pressure for 30min, and diluting with pure water sterilized by filtration to form 6 concentrations of 6g/ml, 3g/ml, 1.5g/ml, 0.75g/ml, 0.375g/ml and 0.1875 g/ml.
The beneficial effects are that:
the Qing Sang Fang disclosed by the invention has the effects of clearing heat and detoxicating, relieving exterior syndrome and ventilating the lung, and has the effects of strengthening body resistance (improving immunity). The qing Sang Fang provided by the invention not only has a better curative effect in clinic, but also takes up a great advantage in price, and obtains higher acceptance of parents of children patients.
According to the invention, the influence of the green Sang Fang on the hemagglutination titer of the influenza virus in the chick embryo and the treatment effect of infected mice are researched by two experimental examples, so that a theoretical basis is provided for resisting the influenza virus in the traditional Chinese medicine; experiments show that the green Sang Fang has an inhibiting effect on the hemagglutination titer of the influenza virus, can improve the symptoms, the weight, the lung index, the pathological manifestations and the scores of mice, and proves the reliability of the formula.
Drawings
The accompanying drawings are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate the invention and together with the embodiments of the invention, serve to explain the invention.
In the drawings:
FIG. 1 is a 24h histogram of the mean viral titer of each group of example 1;
FIG. 2 is a histogram of the mean value of the viral titers of each group for 48h in example 1;
FIG. 3 is a graph of the redistribution of the various groups: a: a base weight; b: successful molding; c: day 1; d: day 2; e: day 3; f: day 4; g: day 5; h: day 6; day 7;
Fig. 4 shows lung tissue pathology in mice of each group: a: blank group; b, model group; c: a high concentration group; d: medium concentration group; e: a low concentration group; f: an OS group;
fig. 5 is a group pathology score histogram.
Detailed Description
For the purpose of making the objects, technical solutions and advantages of the embodiments of the present invention more apparent, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention, and it is apparent that the described embodiments are some embodiments of the present invention, but not all embodiments of the present invention. The components of the embodiments of the present invention generally described and illustrated in the figures herein may be arranged and designed in a wide variety of different configurations.
Thus, the following detailed description of the embodiments of the invention, as presented in the figures, is not intended to limit the scope of the invention, as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Modern pharmacological research of Qing Sang Fangzu
Folium Isatidis (a leaf of Isatis tinctoria) is known to have effects of clearing heat, cooling blood and removing toxic substances in traditional medicine, and researchers find that it can effectively inhibit in vivo influenza virus proliferation, clear heat, detumescence and enhance human immune system function ] . The mulberry leaf contains a large amount of beta-sitosterol, and the active ingredient can prevent mice from infecting deadly influenza A and improve immune disorder, and can inhibit inflammatory reaction in cells infected by influenza A virus through signals such as NF-kappa B, MAPK and the like.
The rhizoma Phragmitis extract not only has inhibiting effect on Staphylococcus aureus, but also can inhibit herpesvirus replication without affecting cell physiological activity. Reed rhizome also reduces pain response from inflammation, which may be associated with anti-inflammatory and antioxidant activity. Bai Huang belongs to a heat-clearing herb, which is dedicated to purging fire of upper energizer.
Baicalin and baicalein in baikal skullcap root belong to flavonoids, and the anti-influenza virus mechanism is related to inhibiting the activity of host epithelial cell sialidase, fusion of influenza virus and cell membrane and budding process of influenza virus, and apoptosis enzyme, inflammatory factor and oxidoreductase are interfered by flavonoid substances in baikal skullcap root to reduce influenza A lung injury. The influenza virus usually causes high fever of organism, and researches show that the gypsum has compact structure, small pore diameter, anti-inflammatory effect, and can reduce the body temperature of the fever rats, and the fever mechanism can inhibit NF-kB signal path and reduce the PGE as a fever medium 2 Related to the following.
Chlorogenic acid in flos Chrysanthemi can promote production of interferon and tumor necrosis factor in human lymphocyte and peripheral leukocyte, and inhibit proliferation of influenza virus.
Bitter almonds can significantly reduce the immune injury of the lung and intestinal tracts of influenza mice, and the action mechanism is possibly related to inhibiting the release of TNF-alpha and IL-6 in the serum of the influenza mice and down regulating the expression level of TLR7 protein.
Ningpo Yam rhizome contains a naturally occurring steroid saponin which not only can block virus infection in the initial stage, but also can reduce the sensitivity of host cells to virus infection and inhibit airway inflammation indexes (such as IL-6 and IL-1 beta) of asthmatic mice. Triterpenes present in licorice can prevent fusion of influenza virus with host epithelial cell membrane in early stage, so that virus replication activity after infection of cells is inhibited.
Based on the pharmacological mechanism and clinical treatment experience, an anti-influenza virus traditional Chinese medicine composition is developed and comprises dyers woad leaf, mulberry leaf, reed rhizome, baical skullcap root, gypsum, chrysanthemum, bitter apricot seed, ningpo Yam rhizome and liquoric root.
The proportion of each component is as follows: 15 parts of dyers woad leaf, 9 parts of mulberry leaf, 12 parts of reed rhizome, 9 parts of baical skullcap root, 30 parts of gypsum, 6 parts of chrysanthemum, 6 parts of bitter apricot seed, 9 parts of Ningpo Yam rhizome and 4 parts of liquoric root.
A preparation method of an anti-influenza virus traditional Chinese medicine composition comprises the following steps:
step 1: decocting 3 agents, namely 300g of gypsum with 300ml of pure water with strong fire for 15-30min;
step 2: 150 parts of dyers woad leaf, 90 parts of mulberry leaf, 120 parts of reed rhizome, 90 parts of baical skullcap root, 60 parts of chrysanthemum, 60 parts of bitter apricot seed, 90 parts of Ningpo Yam rhizome and 40 parts of liquorice are added into the medicine in the step 1, and 1500ml of pure water is added for soaking for 1 hour;
step 3: heating and decocting all the medicines in the step 2 with slow fire to 300mL, filtering the decoction with 4 layers of sterile gauze, collecting the filtered decoction, adding 1500mL of pure water into the residual filter residue, heating and decocting with slow fire to 300mL again, repeating the filtering and decocting operation for 5 times, finally combining the 5 times of filtrates, and concentrating the medicines to 6g/mL;
step 4: sterilizing the medicine prepared in the step 3 at high temperature and high pressure for 30min, and diluting with pure water sterilized by filtration to form 6 concentrations of 6g/ml, 3g/ml, 1.5g/ml, 0.75g/ml, 0.375g/ml and 0.1875 g/ml.
Furthermore, the traditional Chinese medicine composition can be prepared into water aqua, oral liquid, granules and the like.
Example 1: experiment of anti-H1N 1 influenza A virus in green Sang Fang chicken embryo
1 materials and instruments
1.1 viral strains
The murine lung adapted strain is the strain A H1N1 virus NYMCX-179A (titre of viral fluid hemagglutination 1:640) and is supplied by the laboratory animal center of Jiangsu Dike Biotechnology Co., ltd. All influenza virus tests were performed in the biosafety laboratory class II (ABSL-2).
1.2 therapeutic agents
(1) Green Sang Fang
The prescription is composed of 9 traditional Chinese medicines (15 g of dyers woad leaf, 9g of mulberry leaf, 12g of reed rhizome, 9g of baical skullcap root, 30g of gypsum (decocted first), 6g of chrysanthemum, 6g of bitter apricot seed, 9g of Ningpo Yam rhizome and 4g of liquoric root), 100g in total, and is purchased in a second affiliated hospital of Shanxi traditional Chinese medicine university, and is identified as a genuine product by the university of medicine university, and the medicine dosage accords with 2020 edition of Chinese pharmacopoeia.
(2) Control drug
Oseltamivir capsules (manufacturer and trade name are Changjiang pharmaceutical industry Co., ltd., and kewei, product lot number: H20065415, respectively).
1.3 Experimental chick embryo
SPF grade fertilized chick embryo without pathological change, 9-11 days old, provided by Hangzhou Xiaoshan Wei farm.
1.4 chicken erythrocyte suspension
Fresh cock blood is taken from healthy cock bred in laboratory animal center of Jiangsu Dike Biotechnology Co., ltd, after being anticoagulated by adding Aldrich solution, the mixture is centrifuged for 3 times by using 0.9% NaCl solution, the time is controlled to be about 10 minutes, the upper serum and the leucocyte layer of the centrifuge tube are fully sucked to leave chicken erythrocytes, 49.5ml of 0.9% sterile normal saline solution is sucked by using a micropipette, 0.5ml of chicken erythrocytes are added to prepare 1% sterile erythrocyte suspension according to a proportion, and the preservation condition is 4 ℃.
1.5 instruments
The experimental field and equipment are all provided by Jiangsu Dike Biotechnology Co., ltd.
Name of the name | Company (Corp) | Model number |
Biological safety cabinet | Jiangsu purifying plant | BBS-SDC |
Refrigerator with a heat exchanger | Qingdao sea | HYC-1378 |
Centrifugal machine | Hunan instruments laboratory instruments Co.Ltd | TDZ5-WS |
Pressure steam sterilizing pot | LICHEN | DGS-280B |
Water bath kettle | Rui-stationary instrument and equipment factory | DK-S11 |
Water purifier | Shanghai Lei Ci | UPW-H2-15 |
Chick embryo incubator | Plain hatching equipment factory | ZX-88 |
96-well plate | Biyundian biotechnology Co.Ltd | FPT0166 |
Liquid transfer device | EPPENDORF | Q37533 |
2. Method of
2.1 pharmaceutical preparation
(1) Decocting green Sang Fang
300g (3 doses) of green Sang Fangzhong gypsum is firstly decocted with 300mL of pure water with strong fire for 15-30min, then 1500mL of pure water is added and the rest of the medicines are soaked for about 1 hour, all the medicines are heated and decocted again with slow fire to 300mL, the medicine juice is collected after being filtered by 4 layers of sterile gauze, 1500mL of pure water is added into the residual filter residue and heated and decocted again with slow fire to 300mL, the filtering and the decoction operation are repeated for 5 times, and finally the 5 times of filtrate are combined and the medicines are concentrated to 6g/mL. In order to avoid bacteria in the medicine polluting chick embryo, the medicine with the concentration is sterilized at high temperature and high pressure for 30min, and then diluted by pure water which is filtered and sterilized to form 6 concentrations of 6g/ml, 3g/ml, 1.5g/ml, 0.75g/ml, 0.375g/ml, 0.1875g/ml and the like, and each diluted concentration is used for the experiment of the lowest lethal concentration of the medicine on chick embryo. The remaining 3g/ml concentration of the medicine is used as an antiviral medicine in chicken embryo bodies for standby.
(2) Oseltamivir
300mg OS is added into 10ml pure water to prepare 30mg/ml sterile suspension, and the sterile suspension is diluted into 15mg/ml, 7.5mg/ml, 3.75mg/m, l.88mg/ml and 0.94mg/ml, and the 6 concentrations are used as the lowest lethal concentration experiment of chick embryo for standby. 225mgOS is added into 100ml of pure water to prepare 2.25mg/ml of medicine solution which is used as an antiviral medicine in chicken embryo body for standby.
2.2 influenza Virus chick embryo amplification
Taking 9-11 days old chick embryo, using a marker pen to mark the boundary between the air chamber and the embryo after the chick embryo is photographed in a darkroom, sterilizing eggshells at the air chamber part by alcohol, and opening a small opening with the length of about 2mm at the position about 1mm on the line and avoiding a conical eggbeater for blood vessels, thus obtaining the injection point. The virus stock (titer 1:640) was removed from-80 ℃, the centrifuge tube was rinsed with natural running water to thaw the virus, and 0.2ml of virus solution was injected per chick embryo, 5 total chick embryos, and the syringe was required to penetrate the allantoic membrane and avoid puncturing chick embryo blood vessels. And (3) after melting paraffin in an alcohol burner flame, plugging small holes in eggshells of the chick embryos, adjusting the temperature of an incubator to 33-35 ℃, incubating the chick embryos for 48 hours, harvesting allantoic fluid, observing survival conditions of the chick embryos inoculated for 24 hours and 48 hours, and removing dead chick embryos caused by improper operation in 24 hours. The chick embryos are placed in a refrigerator at-20 ℃ for 1-2 hours before harvest, and care should be taken not to excessively long to avoid freezing allantoic fluid into a solid. The eggshells are disinfected again before the allantoic fluid is harvested, eggshells at the top of the air chamber are knocked out by using a pair of sterilizing scissors, the allantoic membrane is broken by using the needle point of a disposable sterile syringe, the needle point of the syringe avoids blood vessels to extract the allantoic fluid after the chick embryos are inclined, and 5-10ml of allantoic fluid is extracted from each chick embryo.
2.3 detection of the hemagglutination titre of Virus fluid
Extracting 5ul of the harvested virus allantoic fluid, adding the first hole at the left side on a 96-well plate, adding 45ul of physiological saline, and repeatedly and uniformly blowing by a pipetting gun to obtain 1:10 virus liquid, adding 25ul of physiological saline into each row of the remaining 11 holes, then sucking 25ul of influenza virus liquid 1:10 from the 1 st hole, adding the 2 nd hole, sequentially diluting the solution to the 11 th hole by 2 times, discarding 25ul of virus diluent sucked by the 11 th hole, and only keeping 25ul of physiological saline in the 12 th hole as a blank control; after 1% of fresh chicken red blood cells are blown and sucked uniformly, the chicken red blood cells are sequentially added into each plate hole, 25 ul/hole is vibrated for 15 seconds, then the chicken red blood cells are kept stand for 30 seconds, the result is observed, the virus titer is calculated according to relevant standards, and allantoic fluid with higher titer is selected and placed at 4 ℃ for standby.
2.4 experiments with lowest lethal concentration of drug
The aim of the experiment of the lowest lethal concentration of the drug is to ensure the safe and reliable concentration of the drug used for resisting influenza virus in the chick embryo. After wet sterilization of 6g/ml of green Sang Fanggao under high pressure and 2-fold serial dilution, 6 gradient drugs (6 g/ml-0.1875 g/ml) were obtained. Each gradient was inoculated with 5 chick embryos, 0.2ml each. After filtration sterilization at 30mg/ml OS, 2-fold serial dilutions (30 mg/ml-2.5 mg/ml) were made for a total of 6 gradients, inoculated virus amounts and chick embryo numbers were identical to those of green Sang Fang. Blank 5 chick embryos were not subjected to any treatment. The total number of the 13 groups is 65 chick embryos, the incubation condition of the incubator is 34+/-1 ℃, the survival condition is observed in 24h, the death caused by improper operation is eliminated, the survival condition is observed in 72h, and the lowest concentration of chick embryo death is regarded as the lowest lethal concentration.
2.5 research on anti-influenza Virus efficacy of Qing Sang Fang in chick embryo
The SPF fertilized chick embryos without lesions were selected and randomly divided into 14 groups of green Sang Fang, oseltamivir (OS) 6, virus positive, blank, 12 chick embryos each, 9-11 days old. Because there is no embryo correlation coefficient in the human and animal dose conversion, the highest concentration used in this study of embryos is consistent with the highest concentration used in subsequent mice experiments. Sterilizing green Sang Fang (3 g/ml) in biosafety cabinet according to 2 -1 -2 -6 Dilution of 6 gradients (Green Sang Fang 2 -1 Consistent with the high dose of mice, i.e., 1500 mg/ml), 3ml of each gradient was taken and added with an equal amount of virus stock (titer 1:640), incubated in a 37℃water bath for 1 hour, and inoculated into chick embryos at 0.2ml per each gradient.OS (2.25 mg/ml) was first pressed 2 -1 -2 -6 Dilution of 6 gradients (OS 2 -1 At the same mouse dose, i.e., 1.125 mg/ml), the remaining treatments were performed on the same green Sang Fang group. The positive group was taken from 3ml of PBS solution and added with an equal amount of virus stock, and the blank group was not treated at all before incubation and inoculation. Virus hemagglutination titers in each group of chicken embryo were measured at 24h and 48h post inoculation.
2.6 statistical analysis
ˉ
Statistical software is graphpadrism, data of measurement data are represented by X+ -S, single-factor analysis of variance is used, multiple comparisons are selected, average value of each column is compared with average value of each other column, and P < 0.05 is statistically significant.
3 results
3.1 virus hemagglutination titre after chick embryo expansion
Observations and recordings on 96-well plates, where positive indicates a "#, ++, +,", negative is indicated as "-". "+" indicates that a small lump with unsmooth edges is formed in the plate hole, and small agglomerations are gathered around the small lump; "++" is only formed into a ring, there is no agglutination in the ring, and there are small agglomerations around it; tidy and tidy degree of uniformity of degree better than "++", but not as much as "#", the uniform coverage area in the plate holes is larger; "#" represents binding of influenza virus hemagglutinin to the red blood cell mucin receptor, with red blood cells evenly spread across the plate wells; the red blood cells in the negative "-" plate holes form a red cluster with smooth edges. Table 1 shows that most of the hemagglutination titers of the influenza viruses tested after replication and amplification can be maintained at 1:640, extracting the allantoic fluid of the chick embryo as virus stock for later use.
TABLE 1 titers of influenza virus chick embryos after expansion
3.2 minimum lethal concentration of drug
The chick embryo death phenomenon starts to appear at the time of 6g/ml and 15mg/ml of green Sang Fang and OS respectively, the lowest lethal concentration of green Sang Fang is 6g/ml, and oseltamivir is 15mg/ml. So that the subsequent chick embryoMaximum concentration of the two drugs in the in vivo antiviral assay (Green Sang Fang 2 -1 And oseltamivir 2 -1 ) Are within a safe range.
Table 2 lowest lethal concentration of drug
3.3 antiviral results in green Sang Fang chick embryo
The positive group had higher virus titers at both 24h and 48h than the corresponding blank group (P < 0.05). In the aspect of drug treatment, compared with a virus positive group, the green Sang Fang and the OS can inhibit influenza viruses at 24 hours and 48 hours (P is less than 0.05). Green Sang Fang at 24h and 48h was 2 compared to OS group -1 、2 -2 、2 -3 The difference in concentration from the corresponding OS group was not statistically significant (P > 0.05), especially 2 -1 、2 -2 At concentration, both green Sang Fang and OS virus titers were 0; but green Sang Fang 2 -4 、2 -5 、2 -6 The virus titers at the concentrations were higher than the corresponding OS group at both 24h and 48h, with statistical differences (P < 0.05). From a time comparison, except for the foregoing cyan Sang Fang 2 -1 、2 -2 The infusion was 0 at both times, 48h green Sang Fang 2 -3 、2 -4 The mean value of the concentration virus titers is higher than the corresponding 24h, but the statistics show that the difference is not significant (P > 0.05); 48h green Sang Fang 2 -5 、2 -6 The virus titer of the concentration group is higher than the corresponding 24h, and the difference is statistically significant (P < 0.05). See table 3 and figures 1 and 2 for details.
TABLE 3 anti-influenza Effect in chick embryo with different concentrations of drug
(note: 0' represents negative reaction, positive to blank ratio: four represents P < 0.05; V represents P < 0.05; compared to positive group; compared to oseltamivir counterpart group): Representing P > 0.05, +.represents P < 0.05; comparison of groups corresponding to 24 h: wherein P is greater than 0.05, and T is less than 0.05. )
Conclusion 4
The influenza virus amplification culture method mainly comprises 3 steps: chicken embryo culture method, animal living body culture method, and animal cell culture method. The chick embryo culture method has the unique advantages of strong virus sensitivity, simple operation, sufficient source, low tissue differentiation degree and the like, and is widely applied to research and development and production of influenza vaccines. The living animals for culturing influenza virus mainly comprise mice, ferrets, chickens, pigeons, pigs, horses and the like, and the most sensitive animals in the living animals are ferrets, but the animals and the raising price are high, and the infection symptoms of the animals such as pigs are not obvious, so the price, the raising and the replicability determine that the mice are most commonly used in influenza experiments. The animal cell culture method mainly utilizes kidney cells of animals such as dogs, monkeys, cattle and the like to amplify influenza viruses, and dog kidney passage cells are tissue cells most commonly used in the cell culture method, and have the advantages of economy, convenience, less allergic reaction and the like, but also have the defects of poor sensitivity, low virus titer, inconvenient preservation and the like.
The simultaneous administration method is one of 3 main administration modes of the anti-influenza virus of the traditional Chinese medicine in the chick embryo. The simultaneous administration method comprises mixing the virus liquid and the Chinese medicinal materials with relevant concentration, incubating at 37deg.C for 1 hr, and injecting into chick embryo at a ratio of 0.2 ml/piece to observe the inhibiting effect of the medicine on influenza virus. The injection quantity of chick embryo needs to be noted, and operational death is avoided. The proliferation of influenza virus occurs 18-72h after the inoculation of the chick embryo, and the current time for detecting the hemagglutination titer of the influenza virus chick embryo is mainly 24h, 48h and 72h after infection.
Therefore, the test uses a simultaneous administration method in chick embryo culture, and the hemagglutination titer is detected 24h and 48h after infection. Experiments show that the hemagglutination titer of the positive group infected with the influenza virus is higher than that of the blank group, which indicates that the influenza virus is successfully replicated in the chick embryo model; cyan Sang Fang 2 -1 -2 -6 (1500 mg/ml-46.88 mg/ml) at 24h and 48h inhibits influenza virus, and overall virus titer is inversely related to concentration;cyan Sang Fang 2 -1 (1500mg/ml)、2 -2 (750 mg/ml) can completely inhibit influenza virus in chicken embryo to give blood coagulation titer of 0, and has effect similar to OS2 -1 、2 -2 The concentration groups are equivalent, which shows that the green Sang Fang and the OS can completely inhibit the influenza virus in chicken embryo bodies, and the minimum concentration of the completely inhibited virus is green Sang Fang 2 -2 (750 mg/ml) and OS2 -2 (562.5 ug/ml). Overall distribution, the titers of the cyan Sang Fang groups were not better than the corresponding OS group, in particular cyan Sang Fang 2 -4 (187.5mg/ml)2 -5 (93.75mg/ml)、2 -6 The virus titer of the (93.75 mg/ml) concentration is higher than that of the corresponding OS group at 24h and 48h, which shows that the anti-influenza effect of the OS still has great advantage, and further intensive research is needed in the aspect of anti-influenza curative effect of the traditional Chinese medicine. From time comparison, the 48h hemagglutination titer of the virus positive group is higher than that of the 24h, which indicates that the influenza virus is proliferated in chicken embryo along with the extension of time (within 48 h), so that the virus proliferation should be inhibited by timely administration after the infection of the influenza virus; low concentration of green Sang Fang (e.g. 2 -5 、2 -6 ) Titers at 48h were higher than 24h, indicating that low concentrations of drug did not completely inhibit the virus, and residual virus continued to proliferate over time suggesting that green Sang Fang anti-influenza virus would be best selected for use in higher dose groups within 24h (e.g., 2 -1 And 2 -2 A group).
The invention discloses a self-made prescription containing 9 traditional Chinese medicines, namely qing Sang Fang, which is obtained through clinical practice, and the syndrome of wind-heat invading exterior is the adaptation type of qing Sang Fang for treating influenza. The green Sang Fang not only has good curative effect in clinic, but also has obvious price advantage compared with oseltamivir, and the traditional Chinese medicine related to the green Sang Fang has huge market potential.
Example 2:
1 test materials
1.1 laboratory animals
108 female SPF-grade BALB/c mice were provided by Jiangsu Hua Xinnuo medical science and technology Co., ltd, and purchased at a weight of 18-20g, lot number: SCXK (su) 2020-009, randomly divided into 6 groups: blank group, model group, green Sang Fanggao, medium and low concentration group and Oseltamivir (OS) group, wherein 18 groups are fed separately, the environment temperature is set to 20-26 ℃, the humidity is automatically set to 40-70%, the complete sterile feed is eaten, and tap water is drunk and sterilized at high temperature and cooled.
1.2 strains
The strain A H1N1 virus NYMCX-179A (murine lung adapted strain) is provided by experimental animal center of Jiangsu Dike Biotechnology Co., ltd, and virus allantoic fluid with a titer of 1:640 is obtained after virus amplification by chick embryo experiment.
1.3 medicaments
(1) Green Sang Fang
As in example 1.
(2) Oseltamivir
As in example 1.
1.4 major equipment
The experimental field and equipment are all provided by Jiangsu Dike Biotechnology Co., ltd.
/>
1.5 major reagents
2 method
2.1 calculation of the dose administered to mice:
(1) Oseltamivir dose conversion
The dose of oseltamivir for adults is 75 mg/time and 2 times/day, so that the clinical dose of 60kg of adults is 2.5mg/kg. According to the conversion coefficient of the medical experiment animal science course, the equivalent dose of mice is 9.01x2.5mg/kg= 22.525 mg/kg=22.5 ug/g, and the daily dose of the mice with 20g is 450ug, and the mice are administrated once in the morning and evening, so that the drug content of each administration is 225ug, each mouse is administrated according to 0.2ml, and the concentration is 1.125mg/ml.
(2) Conversion of the amount of green Sang Fangji
The total weight of the green Sang Fang containing 9 traditional Chinese medicines is 100g, and the clinical dosage of 60kg adults is 1.667g/kg. The remaining calculation method was the same as oseltamivir, and the final clinical equivalent dose of the adult to mice was 750mg/ml, which was also considered as the concentration group in green Sang Fang, the high concentration group was 1500mg/ml, and the low concentration group was 375mg/ml.
2.2 decocting (compounding) the drugs
(1) Green Sang Fang
The 300g green Sang Fang decoction method is the same as that of the first part of chick embryo experiment, 5 times of filtering juice are combined and concentrated to 200mL, and the medicine concentration is 1500mg/mL (high dose group) at the moment, and then the medicine concentration is diluted to medium concentration (750 mg/mL) and low concentration (375 mg/mL) in sequence.
(2) Oseltamivir preparation
225mg of oseltamivir was dissolved in 200ml of pure water, and stirred using a magnetic stirrer to completely dissolve, to finally obtain oseltamivir solution having a concentration of 1.125 mg/ml.
2.3 nasal drop molding die
The blank group compartment is fed to avoid infection, drinking water and food normally without any treatment; the other 5 groups of mice are subjected to nasal drop molding for 2 days, the drop degree of the rhinovirus drops is 1:640, the grabbed mice are kept upright, the pipette tips are aligned to the left nasal cavity and the right nasal cavity of the mice, the nasal drop amount of each nasal cavity is 15 ul/time, 5-7 times a day, and the phenomenon that the nasal drop amount cannot be too large every time is noticed, so that the mice are prevented from choking is avoided. After nasal drip for 2 days, combined with the symptoms and pathological sections of the mice, the model can be clearly established to be successful and regarded as formal infection [128] 。
2.4 administration (Water) and recording of basic Condition
The treatment is carried out by continuously dosing according to the calculated gastric lavage concentration on days 1-5 of the infection of the green Sang Fangzu and OS groups, the dosing is carried out 2 times a day, the interval is 8-12 hours, each time is 0.2 ml/dose, and the water feeding time, frequency and quantity of the model group are equal to those of the drug treatment group; the blank group was normally fed. The basic status of mental state, diet, body weight, respiration, ocular and nasal secretion, etc. of each group of mice was observed and recorded.
2.5 sample acquisition and calculation of Lung index
Each group was 3 rd after infection, 5. 6 mice were randomly picked 7 days for carbon dioxide sacrifice [129] . The sacrificed mice are placed in an alcohol jar for pickling and sterilizing 1, the sterilized mice are placed in a newly opened sterile culture dish in an ultra-clean workbench, the chest cavity is slowly and gently sheared by scissors after high-temperature and high-pressure sterilization, lung tissues are required to be completely taken out under the precise matching of the scissors and forceps, the lung tissue weight is weighed and recorded, and the lung index (lung index = lung weight of mice/body weight of mice x 100%) is calculated. The left and right lungs of the mice were isolated and placed into the formaldehyde tube.
2.6 pathological sections, dehydration and wax dipping embedding. Slicing, dewaxing, staining and observing
The pathological changes are observed under a microscope and photographed by a computer. Pathology scoring is performed according to relevant pathology scoring criteria.
2.7 statistical analysis
Statistical analysis was performed as in example 1.
3 results
3.1 symptomatic manifestations of groups
Before modeling, the mental state, the food intake and the respiration of each group of mice are normal, and secretion does not exist at eyes and noses; compared with normal blank groups, the mice in each group after molding have poor mental state, diet, hair appearance, activity and the like, and abnormal secretion at eyes and noses is increased; after administration of green Sang Fang and oseltamivir, mice of each treatment group had improved mental, hair, activity, etc. aspects; the symptom improving effect of the mice in the green Sang Fanggao concentration group is better than that of the mice in the middle and low concentration groups, but the effect of the mice in the green Sang Fanggao concentration group can not be equivalent to that of oseltamivir by the 5 th day, and the symptoms of the mice in the middle and low concentration groups are consistent. The specific symptoms of each group are shown in Table 4.
Table 4 symptomatic manifestations of each group
3.2 weight changes
The basis body weights of the mice in each group were approximately equivalent before molding. Compared with blank groups, the weight of each group is obviously reduced (P is less than 0.05) after the molding is successful, and each group of mice does not die after the molding. Model group body weight fell to nadir on day 5, with a minimum average body weight of 15.33g, and slowly rising after that, but still lower than the blank group body weight (P < 0.05); at various time points after formal treatment, both green Sang Fang and oseltamium Wei Tichong were higher than model group (P < 0.05); on days 1 and 2, green Sang Fang had still a decreasing trend in body weight, but green Sang Fang had consistently higher body weight than model group (P < 0.05); the decrease trend was discontinued for each drug group on day 3 of treatment, and the mice body weight was gradually increased after that, especially on day 7, there was no significant difference between the body weight of the cyan Sang Fanggao concentration group and the OS group and the blank group (P > 0.05).
Table 5 weight distribution table for mice in each group
Comparison of base body weight: wherein P is > 0.05; compared to the blank:representing P > 0.05, +.represents P < 0.05; comparison with the corresponding set of time point models: delta represents P > 0.05, and V represents P < 0.05.
3.3 Lung index Change
After successful modeling, the lung index of the model group infected with influenza virus was higher than that of the blank group (P < 0.05). On day 3 of infection, the lung index was lower for the cyan Sang Fanggao concentration only group and the OS group than for the model group (P < 0.05). On day 5 of infection, green Sang Fanggao, medium and low concentrations all reduced lung index in infected mice, with differences statistically significant (P < 0.05). On day 7 of infection, treated green Sang Fanggao, medium concentration groups of mice had no significant difference in lung index (P > 0.05) from the blank group, particularly the green mulberry Fang Gao concentration group was the group with lung index reduced to the nearest normal level.
TABLE 3 results of mouse lung index at various time points
Blank comparison, +.; compared to the model set: where R represents P < 0.05 and delta represents P > 0.05.
3.4 pathological lesions of pulmonary tissue
Pathological changes in lung tissue
Blank group: the pulmonary tissue has clear reticular structure, the alveoli are not broken and have no hyperemia phenomenon, and no leukocyte infiltration exists; infection model group: the lung tissue is structurally changed, the alveoli are broken, the reticular structure disappears, the wall thickness of the alveoli is increased, congestion phenomenon exists in the alveoli, oblate concave red blood cells can be seen after enlargement, a large amount of leucocyte infiltration exists at the alveoli interval, and nuclei can be seen after enlargement; OS group: the structural damage is light, the alveoli are complete, the congestion is less, and the leukocyte infiltration is less; cyan Sang Fang: compared with the model group, the alveolar structure of the 3 concentration groups is clearer, the hyperemia phenomenon is less, and the inflammatory infiltration is lighter; group 3 lesion severity exhibited dose effects: high concentration group < medium concentration group < low concentration group; the high concentration group did not show pathology on day 3 and day 5 as compared to the OS group, the network structure was worse, congestion and leukocyte infiltration were more severe; in addition to the blank, the lesion improvement was more pronounced for each group over time, especially on day 7, with the high and low concentration groups restored to normal blank levels, but the medium and low concentration groups did not reach the OS group, as detailed in fig. 4.
3.5 pathology scoring
The lung tissue pathology scoring standard table of the influenza virus mice is prepared by referring to relevant experimental mouse pathology scoring standards at home and abroad. Specific scoring items and scores are shown in Table 4. In the experiment, the pathological scores of the model groups after successful modeling are higher than those of the blank groups (P is less than 0.05); compared with the model group, the green Sang Fanggao, medium and low concentration group and the OS group can reduce the lung tissue pathology scores on days 3, 5 and 7; on days 3 and 5, pathology scores were higher for the cyan Sang Fanggao, medium, low concentration group than for the OS group (P < 0.05); however, no significant difference (P > 0.05) was found between the group at the concentration of azure Sang Fanggao and the group OS on day 7, as shown in Table 5 and FIG. 3.
TABLE 4 pathological scoring criteria
TABLE 5 results of pathological scoring for each group of experiments
Comparison of model group with blank, +.representing P < 0.05, > 0.05 for four P, > 0.05, comparison with model group: wherein P is less than 0.05, and delta is more than 0.05; compared to the oseltamivir counterpart group: ● Represents P < 0.05,representing P > 0.05.
Discussion 4
4.1 symptomatic manifestations in mice
In influenza studies, mice are the most widely used animal model, and inbred mice such as BALB/C and C57BL/6 are used most frequently for the following reasons: (1) easy-to-operate genome, (2) rapid propagation and easy-to-handle, (3) easy-to-feed, (4) low cost, etc [134] . Influenza infected mice show clinical symptoms such as anorexia, poor mental state, reduced activity and the like, and the specific performance depends on the strain of the mice, the virus strain and the challenge dosage. Weight loss and survival in mice are also important indicators of influenza disease severity.
Influenza virus is an important cause of a large number of acute respiratory viral infections in the population, and many symptoms including high fever, aversion to cold, muscle pain and the like are generated after human infection, diarrhea is sometimes generated, and clinical symptoms of influenza are often more serious in infants and the elderly due to poor or weakened immune systems. Unlike humans, influenza virus infected mice often do not develop fever after macrophage increase, but rather exhibit clinical symptoms such as hypothermia, cyanosis and hemoptysis, which are not readily observed in mice. The particularity of the physiological structure of the mice makes it difficult to measure the self-sensation symptoms such as anal temperature, pharyngalgia, muscular soreness and the like by using a thermometer after the mice are infected with influenza viruses, and tongue pulse of the traditional Chinese medicine diagnosis and treatment cannot be observed and experienced on the mice, so that the study can only judge the infection condition by observing and recording the mental state, activity, weight, secretion and the like of the mice, and is similar to the symptom study of other influenza virus infected mice.
In the experiment, the blank group has normal diet and water inflow, and the front and rear symptoms have no obvious change; after the model group mice are successfully modeled, the symptoms of poor mental state, upright hair, unsmooth and smooth hair, tremble whole body, shrinkage to form clusters, reduced activity, wood chip pad, shortness of breath, reduced appetite and water intake, visible secretion at eyes and nose, frequent front limb face washing action and the like appear. The symptoms were also partially relieved after 5 days of water treatment in the model group, possibly associated with increased autoimmunity in mice. The mice of each treatment group of Qing Sang Fang are better in all aspects of spirit, hair, activity and the like, which shows that Qing Sang Fang can improve symptoms of infected mice, and the effect of a high concentration group is better than that of a medium concentration group and a low concentration group (the improvement effect of the symptoms of the two groups is consistent). However, the effect of the high concentration group can not be equivalent to the effect of oseltamivir until the 5 th day, which indicates that oseltamivir can still play an important role.
4.2 weight changes in mice
The study on the weight of the mice is widely applied to the fields of tumors, diabetes and the like, and the weight of the mice can be changed due to the infection of respiratory viruses. The mental state of mice is poor after the mice are infected with viruses, and the food and water intake are reduced to influence the weight, so that the weight of the mice infected with influenza viruses is generally reduced, and other influenza similar researches prove that the mice are changed. In this experiment, the base weights of the mice in each group were not significantly different before molding; the weight of each group was significantly lower than the base weight (P < 0.05) after 2 days of nasal drip, except for the blank group, indicating successful molding. Model group body weight fell to nadir on day 5, with a minimum average body weight of 15.33g, and slowly increased later, possibly associated with a better before improvement in mental state and increased intake after autoimmune improvement; however, the model group body weight was always lower than the blank group, suggesting that the model group was recovering normal body weight as soon as possible, and still required drug intervention. Green Sang Fang each drug treatment group had a higher body weight than the model group (P < 0.05), suggesting that green Sang Fang could improve the body weight of the infected mice. Green Sang Fang treatment groups still showed a decreasing trend in body weight on days 1 and 2, but higher than model group (P < 0.05), indicating that green Sang Fang was able to reduce the extent of body weight loss in infected mice during the first two days of treatment. The concentration of the green Sang Fanggao can play a role similar to that of the OS on the 7 th day, and the weight of the infected mice can be recovered to be normal.
4.3 pulmonary index protection
The Lung index (Lung index) refers to the percentage of total mass of mice by the mass of Lung tissue taken intact from the mice body, and the severity of inflammatory lesions in Lung tissue is usually expressed by the magnitude of the Lung index. Inflammatory lesions may appear in lung tissue of influenza infected mice, and inflammatory exudates and pulmonary congestion edema increase the mass of mouse lung tissue. The more severe the symptoms of infection, the greater the mass of the lung tissue, and the corresponding lung index. The lung index can be used as an index of the protective effect of the drug on the lung tissue of the mice, and can objectively reflect the change degree of inflammatory lesions of the lung tissue. In the experiment, the lung index of the model group is higher than that of the blank group, and the success of model modeling of the mice in the model group is prompted; green Sang Fang can reduce the lung index of the infected mice, but the lung index reduction effect of all concentration groups can be guaranteed by the 5 th day, so that the treatment time is required to be at least 5 days; no obvious difference between the concentrations of green Sang Fanggao and the medium concentration on the 7 th day of infection and the blank group shows that the concentrations of green Sang Fanggao and the medium concentration can restore the lung index of the mice to be normal, wherein the concentration group of green Sang Fanggao is the group with the best curative effect of reducing the lung index.
4.4 pathological manifestations of pulmonary tissue
The reason for choosing formaldehyde as the fixative in this experiment is that formaldehyde is considered a classical solution in the fixation process, has a remarkable ability to penetrate tissue in a short time, ensures less tissue damage, and plays both a role as fixative and preservative, so it is called classical fixative. In the experiment, the lung tissue of the model group has obvious structural change, the alveoli of the mice are broken, the reticular structure disappears, the wall thickness of the alveoli is increased, the congestion phenomenon exists in the alveoli, inflammatory cell infiltration is consistent with similar research at home and abroad, and the authenticity of successful modeling is further proved.
Although the phenomena of network structure damage, alveolar wall thickening, congestion and the like also exist in the mice treated by the green Sang Fang and OS, compared with a model group, the pulmonary alveolus network structure integrity of the mice of the green Sang Fang and oseltamivir 4 drug groups is better, and the phenomena of congestion, leukocyte infiltration, cell nucleus number and the like are fewer, so that the green Sang Fang and oseltamivir have a certain protection effect on lung tissue injury of the mice infected with H1N1 influenza. The severity of lesions in the cyan Sang Fang dose group exhibited a dose effect: the higher the dose, the lighter the lung tissue lesions; the longer the treatment time of each group of green Sang Fang, the lighter the lung tissue lesions, which may be related to antiviral drugs such as dyers woad leaf, baical skullcap root and the like in the prescription, and also may relate to glycyrrhizin in liquorice (inhibiting influenza virus, improving immunity and alleviating immunopathogenic injury of organisms). The high concentration group did not show much pathology as the OS group on days 3 and 5, but the high concentration group and OS group had recovered to normal blank group levels on day 7, indicating that the green Sang Fanggao concentration group exhibited the best anti-influenza effect on day 7, and also suggesting that oseltamivir still had anti-influenza advantage.
4.5 pathology scoring
In this experiment, the scores were mainly based on 5 items of tracheal lumen exudates, substantial pneumonia, peripulmonary vascular infiltration, invasive lesions and qualitative in lung tissue of influenza virus infected mice. The model group pathology scores at 3 time points are higher than that of the blank group (P is less than 0.05), and are always at the highest position in the scores of each group, so that the mice are successfully modeled and the lung tissue injury is serious after being infected by the H1N1 influenza virus. The green Sang Fanggao, medium, low concentration and OS groups reduced lung tissue pathology scores on days 3, 5 and 7, and were statistically different (P < 0.05), indicating that green Sang Fang 3 concentration groups and OS groups both had protective effects on lung tissue in influenza virus infected mice. On days 3 and 5, the pathology scores of the cyan Sang Fang groups are higher than those of the OS group, which shows that the effect of early-stage pathology score reduction is inferior to that of the OS group, and the OS still plays a role in drug selection. The concentration group of cyan Sang Fanggao on day 7 was not statistically different from OS, indicating that the concentration group of cyan Sang Fanggao had a similar effect on OS in reducing pathology scores in infected mice.
Case examples
Case 1:
child, male, 10 years old, complaint: fever cough for more than 2 days, and the current medical history: fever and cough for more than 2 days, diarrhea, no herpes, no rash, no nausea and vomiting, no diarrhea, abdominal distension and other symptoms are generally found in the oral cavity. The appetite is still good, and the urination and defecation are normal. Checking: normal development, moderate nutrition, clear mind and good spirit. Bregma is soft, no yellow staining of skin and mucous membrane, bleeding points and rash, and superficial lymph node is not touching enlargement. The throat is free from congestion, the tonsils are free from swelling, abnormal secretions are not caused, and the oral cavity is free from blepharma. The chest has symmetrical and non-malformation, and the lung breathing is sound-absorbing and clear, and the lung breathing is not smelling and is dry and wet. No abnormality was seen in the abdomen. The limbs can move freely, no deformity exists, and the buttocks and hands do not see the skin. Physiological reflex exists, and pathological reflex is not led out.
Auxiliary inspection: detecting the alpha-influenza antigen, namely, detecting the alpha-influenza antigen positively; mycoplasma pneumoniae antibody IgM: positive.
Diagnosis: wind-heat syndrome, cold; acute upper respiratory tract infection.
The prescription of the traditional Chinese medicine:
5 doses of radix scutellariae 9g of gypsum, 9g of mulberry leaf, 12g of reed rhizome, 15g of dyers woad leaf, 6g of chrysanthemum, 6g of fried bitter apricot seed, 4g of Ningpo Yam rhizome and 4g of liquorice are taken together, one dose is taken every day, 200ml of decoction is taken orally: 100ml of the preparation is taken 2 times a day
The curative effect of the following treatment: the medicine is taken on day 3, and symptoms disappear on day 5.
Case 2:
child, woman, 13 years old, complaint: fever and headache are more than 1 day. The current medical history: fever for more than 1 day, headache, cough, expectoration, no herpes, no rash, no nausea, no vomiting, no diarrhea, no abdominal distention and other symptoms. The appetite is still good, and the urination and defecation are normal. Checking: normal development, moderate nutrition, clear mind and good spirit. Bregma is soft, no yellow staining of skin and mucous membrane, bleeding points and rash, and superficial lymph node is not touching enlargement. The throat is free from congestion, the tonsils are free from swelling, abnormal secretions are not caused, and the oral cavity is free from blepharma. The chest has symmetrical and non-malformation, and the lung breathing is sound-absorbing and clear, and the lung breathing is not smelling and is dry and wet. No abnormality was seen in the abdomen. The limbs can move freely, no deformity exists, and the buttocks and hands do not see the skin. Physiological reflex exists, and pathological reflex is not led out.
Auxiliary inspection: blood routine WBC 3.3X109/L NEUT 33.6NEUT#1.1CPR <10mg/L hCPR1.69mg/L, and influenza A antigen detection; mycoplasma pneumoniae antibody IgM: negative.
Diagnosis: wind-heat syndrome, cold; acute upper respiratory tract infection.
The prescription of the traditional Chinese medicine:
3 doses of radix scutellariae 9g of gypsum, 9g of mulberry leaf, 12g of reed rhizome, 15g of dyers woad leaf, 6g of chrysanthemum, 6g of fried bitter apricot seed, 4g of Ningpo Yam rhizome and 4g of liquorice are taken orally, wherein one dose is decocted with 200ml of water every day: 100ml each time 2 times daily.
The curative effect of the following treatment: symptoms are relieved on the 3 rd day of administration, and symptoms disappear on the 5 th day.
Case 3:
child, male, 3 years old, complaint: fever cough for 1 day, history of illness: in general, the oral cavity has no herpes, no rash, no nausea and vomiting, no diarrhea, no abdominal distention and other symptoms. The appetite is still good, and the urination and defecation are normal. Plain body is healthy. Checking: normal development, moderate nutrition, clear mind and good spirit. Bregma is soft, no yellow staining of skin and mucous membrane, bleeding points and rash are seen, and superficial lymph nodes are not touching enlargement. The throat is free from congestion, tonsils are free from swelling, abnormal secretion is not seen, and the oral cavity is free from herpes. The chest has symmetrical and non-malformation, and the lung breathing is sound-absorbing and clear, and the lung breathing is not smelling and is dry and wet. No abnormality was seen in the abdomen. The limbs can move freely without deformity, and the skin is not seen on the buttocks and hands. Physiological reflex exists, and pathological reflex is not led out. Auxiliary inspection: blood routine shows: n%71%, LYMPH%:17.7%, EOS%2%, PLT 356X 10 9 L, PCT 0.3, SAA 16. And detecting the alpha-influenza antigen, namely positive. Mycoplasma pneumoniae antibody IgM: negative.
Diagnosis: wind-heat syndrome, cold; acute upper respiratory tract infection
The prescription of the traditional Chinese medicine:
6g of mulberry leaf, 6g of dyers woad leaf, 15g of gypsum and 5g of fried bitter apricot seed
Chrysanthemum flower 4g, baikal skullcap root 4g, ningpo Yam rhizome 4g, licorice root 3g, reed rhizome 6g
Total 5 doses, one dose per day, water decoction 200ml, oral: 100ml of the preparation is taken 2 times a day
The curative effect of the following treatment: after taking 3 doses, symptoms are relieved, symptoms disappear for one week, and the SAA <5 is obviously reduced before the outpatient inspection.
Case 4:
child, female, age 2, complaint: heating for 1 day. The current medical history: fever appears after catching cold before 1 day, the highest temperature is 38.7 ℃, cough, paroxysmal, phlegm, difficult expectoration, no chills and convulsion, nausea and vomiting, morbidity, excessive appetite and normal urination and defecation are caused. Checking: the mind is clear and the spirit is good. Smooth breathing, reddish throat, no swelling of tonsil, white and thick tongue coating, thick sound absorption of double lung breathing, no smell and dry and wet sound. No abnormality was seen in the examination of the heart, abdomen and nervous system.
Auxiliary inspection: blood convention: weak positive, MONO%15.2CPR <10mg/L hCPR1.22mg/L alpha-stream antigen detection; mycoplasma pneumoniae antibody IgM: negative.
Diagnosis: cold with excessive pathogenic factors (wind-heat syndrome), influenza.
The prescription of the traditional Chinese medicine:
radix scutellariae 6g gypsum 12g mulberry leaf 6g reed rhizome 4g dyers woad leaf 6g chrysanthemum 5g fried bitter apricot seed 3g Ningpo Yam rhizome 5g liquorice 3g total 5 dose, one dose per day, water decoction 200ml, oral administration: 100ml each time 2 times daily.
The curative effect of the following treatment: the symptoms are relieved on the 4 th day of administration, and the symptoms disappear on the 5 th day.
Case 5:
child, male, 5 years old, complaint: heating for 2 days for repeated diagnosis; the current medical history: : the infant has no obvious cause of fever before 2 days, the maximum body temperature is 38.4 ℃, no shivering or convulsion exists, and the body temperature is reduced to be normal after physical cooling; with pharyngalgia, headache, cough, expectoration, nasal obstruction, nasal discharge, nausea, emesis, abdominal distention and diarrhea, the family members can take the oral antiphlogistic antipyretic mixture (not detailed) by themselves, and still generate heat, thus the patient can visit the hospital further. The sick children have the symptoms of mental and appetite, normal urination and defecation. Checking: the health-care food has the advantages of clear mind, stable respiration, reddish throat, no tonsil swelling, white and thick tongue fur, thick sound absorption of double lung breathing, inaudible dry and wet sound. No abnormality was seen in the examination of the heart, abdomen and nervous system.
Auxiliary inspection: blood routine WBC 3.26X109/L LYMPH%17.7 CPR <28.3mg/LhCPR >10mg/L alpha-stream antigen detection; mycoplasma pneumoniae antibody IgM: negative.
Diagnosis: wind-heat syndrome, cold; acute upper respiratory tract infection
The prescription of the traditional Chinese medicine:
5 doses of radix scutellariae, gypsum 15g, mulberry leaf, reed rhizome, dyers woad leaf, chrysanthemum 6g, fried bitter apricot seed 4g, ningpo Yam rhizome 4g and liquorice 4g are taken together, one dose is taken every day, water decoction is carried out for 200ml, and oral administration is carried out: 100ml each time 2 times daily. The curative effect of the following treatment: six days later, the conventional CPR of the outpatient blood is obviously reduced by 18.3mg/L hCPR8.87mg/L compared with the prior method
The curative effect of the following treatment: the symptoms are obviously relieved after taking the medicine, and the symptoms disappear after 6 days.
The foregoing has shown and described the basic principles, principal features and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, and that the above embodiments and descriptions are merely illustrative of the principles of the present invention, and various changes and modifications may be made without departing from the spirit and scope of the invention, which is defined in the appended claims. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (3)
1. An anti-influenza virus traditional Chinese medicine composition is characterized in that: comprises folium Isatidis, folium Mori, rhizoma Phragmitis, scutellariae radix, gypsum Fibrosum, flos Chrysanthemi, semen Armeniacae amarum, ningpo Yam rhizome and Glycyrrhrizae radix.
2. The anti-influenza virus traditional Chinese medicine composition according to claim 1, wherein the anti-influenza virus traditional Chinese medicine composition is characterized in that: the proportion of each component is as follows: 15 parts of dyers woad leaf, 9 parts of mulberry leaf, 12 parts of reed rhizome, 9 parts of baical skullcap root, 30 parts of gypsum, 6 parts of chrysanthemum, 6 parts of bitter apricot seed, 9 parts of Ningpo Yam rhizome and 4 parts of liquoric root.
3. A preparation method of an anti-influenza virus traditional Chinese medicine composition is characterized by comprising the following steps: comprising the following steps:
step 1: decocting 3 agents, namely 300g of gypsum with 300ml of pure water with strong fire for 15-30min;
step 2: 150 parts of dyers woad leaf, 90 parts of mulberry leaf, 120 parts of reed rhizome, 90 parts of baical skullcap root, 60 parts of chrysanthemum, 60 parts of bitter apricot seed, 90 parts of Ningpo Yam rhizome and 40 parts of liquorice are added into the medicine in the step 1, and 1500ml of pure water is added for soaking for 1 hour;
step 3: heating and decocting all the medicines in the step 2 with slow fire to 300mL, filtering the decoction with 4 layers of sterile gauze, collecting the filtered decoction, adding 1500mL of pure water into the residual filter residue, heating and decocting with slow fire to 300mL again, repeating the filtering and decocting operation for 5 times, finally combining the 5 times of filtrates, and concentrating the medicines to 6g/mL;
step 4: sterilizing the medicine prepared in the step 3 at high temperature and high pressure for 30min, and diluting with pure water sterilized by filtration to form 6 concentrations of 6g/ml, 3g/ml, 1.5g/ml, 0.75g/ml, 0.375g/ml and 0.1875 g/ml.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310648820.0A CN116637158A (en) | 2023-06-02 | 2023-06-02 | Anti-influenza virus traditional Chinese medicine composition and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310648820.0A CN116637158A (en) | 2023-06-02 | 2023-06-02 | Anti-influenza virus traditional Chinese medicine composition and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116637158A true CN116637158A (en) | 2023-08-25 |
Family
ID=87618616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310648820.0A Pending CN116637158A (en) | 2023-06-02 | 2023-06-02 | Anti-influenza virus traditional Chinese medicine composition and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116637158A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101322810A (en) * | 2008-07-30 | 2008-12-17 | 吉林华康药业股份有限公司 | Chinese traditional medicine composition for treating diabetes respiratory tract infection |
CN104971242A (en) * | 2015-06-17 | 2015-10-14 | 马小平 | Mulberry leaf and chrysanthemum flower granules for treating common cold and preparation method of mulberry leaf and chrysanthemum flower granules |
CN113197981A (en) * | 2021-06-03 | 2021-08-03 | 吉林华康药业股份有限公司 | Application of Shuqing granules in preparation of medicine for treating novel coronavirus pneumonia |
-
2023
- 2023-06-02 CN CN202310648820.0A patent/CN116637158A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101322810A (en) * | 2008-07-30 | 2008-12-17 | 吉林华康药业股份有限公司 | Chinese traditional medicine composition for treating diabetes respiratory tract infection |
CN104971242A (en) * | 2015-06-17 | 2015-10-14 | 马小平 | Mulberry leaf and chrysanthemum flower granules for treating common cold and preparation method of mulberry leaf and chrysanthemum flower granules |
CN113197981A (en) * | 2021-06-03 | 2021-08-03 | 吉林华康药业股份有限公司 | Application of Shuqing granules in preparation of medicine for treating novel coronavirus pneumonia |
Non-Patent Citations (3)
Title |
---|
呼洁,等: "疏清颗粒对EV71的体外抗病毒研究", 湖南中医药大学学报, vol. 33, no. 12, 25 December 2013 (2013-12-25), pages 3 * |
程小宁,等: "穴位贴敷配合西药治疗小儿急性喉炎临床观察", 陕西中医, vol. 38, no. 05, 5 May 2017 (2017-05-05), pages 636 - 637 * |
高奶荣,等: "哮喘患儿布地奈德雾化吸入治疗的临床研究", 实用临床医药杂志, vol. 24, no. 14, 23 July 2020 (2020-07-23), pages 63 - 66 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20120034770A (en) | A medicinal composition for the treatment of bronchitis and preparation thereof | |
CN113350439B (en) | Application of traditional Chinese medicine composition in preparation of antiviral drugs | |
CN112353855A (en) | Application of traditional Chinese medicine composition in preparation of medicine for adjuvant therapy of novel coronavirus pneumonia | |
CN100348258C (en) | Medicine for treating upper respiratory tract infection and preparation method thereof | |
CN102895326B (en) | Traditional Chinese medicine composition for treating infantile common cold and preparation method for traditional Chinese medicine composition | |
CN105998599A (en) | Traditional Chinese medicine composition for treating viral respiratory tract infection and preparation method thereof | |
CN100353953C (en) | Traditional Chinese medicina preparation for treating oral cavity, throat disease and its preparation method | |
CN103961412B (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
CN103494927B (en) | Traditional Chinese medicine composition for treating chicken respiratory disease and preparation method thereof | |
CN112294911A (en) | Traditional Chinese medicine composition for treating cough with lung heat | |
CN105726631A (en) | Application of officinal magnolia bark extract to prepare medicine for treating cow mastitis | |
CN115105502B (en) | Application of compound containing stephania plant alkaloid in preparation of cat infectious peritonitis medicine | |
CN103041030A (en) | Pharmaceutical composition for treating fever with swollen head, as well as preparation method and application thereof | |
CN102139051A (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
CN114796183B (en) | Application of leonurine in preparing medicine for preventing or treating respiratory diseases | |
CN116637158A (en) | Anti-influenza virus traditional Chinese medicine composition and preparation method thereof | |
CN102198192B (en) | Traditional Chinese medicine composition for treating HINI and application thereof | |
CN111084862B (en) | Traditional Chinese medicine oral liquid for preventing and treating lung heat cough and asthma of poultry and preparation method thereof | |
CN113908149A (en) | Application of formononetin in preparation of medicine for preventing and treating acute lung injury | |
CN107375866A (en) | A kind of purposes of Chinese medicine composition in preparing for the somatotrophic medicine of piglet health care | |
CN102327521A (en) | Traditional Chinese medicine composition and decoction-free granules for treating senile pneumonia and preparation method of decoction-free granules | |
CN106924448B (en) | Pharmaceutical composition for treating wind-heat type common cold and preparation method thereof | |
CN110664888A (en) | Anti-inflammatory and antibacterial pharmaceutical composition, and preparation method and application thereof | |
CN111920899B (en) | Medicine for treating cold with syndrome of exterior cold and interior heat and preparation method thereof | |
CN115607614B (en) | Traditional Chinese medicine composition for treating colibacillosis of livestock and poultry and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |